Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MERIT: A Randomized, Double-blind, Placebo-controlled Study of AXS-05 for Relapse Prevention in Treatment Resistant Depression

NCT04608396 is registered in ClinicalTrials.gov with Axsome Therapeutics, Inc. as lead sponsor.

NCT NCT04608396
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04608396 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MERIT: A Randomized, Double-blind, Placebo-controlled Study of AXS-05 for Relapse Prevention in Treatment Resistant Depression
Lead sponsor
Axsome Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 13, 2020
Completion date
July 30, 2021
Enrollment
44 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder, treatment resistant depression